Skip to Main Content
Frequently Asked Questions
Submit an ETD
Global Search Box
Need Help?
Keyword Search
Participating Institutions
Advanced Search
School Logo
Files
File List
Reyes-Ryan_Masters Thesis_Final.pdf (989.63 KB)
ETD Abstract Container
Abstract Header
Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy
Author Info
Reyes, Ryan
Permalink:
http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086
Abstract Details
Year and Degree
2016, Master of Science, Ohio State University, Biomedical Sciences.
Abstract
Sorafenib therapy has been shown to have only a small clinical benefit for liver cancer patients. There is an urgent needed to develop new therapeutic strategies for the treatment of advanced stage HCC. In this report, we screened several repurposed therapeutics in order to identify synergistic drug combinations. We demonstrate that the combination of 2-deoxy-glucose and sorafenib drastically inhibit HCC cell viability in Hep3B, Huh7 and sorafenib resistant Huh7 cells. Cell cycle analysis revealed that this therapeutic combination induced complete G0/G1 arrested HCC cells. Our studies suggest that this cell-cycle arrest is due to the depletion of cellular ATP. Overall, this report provides strong evidence for the clinical potential of sorafenib + 2-deoxyglucose combination therapy.
Committee
Samson Jacob, PhD (Advisor)
Kalpana Ghoshal, PhD (Committee Member)
Pages
30 p.
Subject Headings
Medicine
;
Molecular Biology
;
Therapy
Keywords
Sorafenib
;
2-Deoxyglucose
;
2DG
;
Combination therapy
;
Synergy
;
Sorafenib Resistance
;
Liver Cancer
;
HCC
;
Cell cycle arrest
;
Proliferation
;
Growth
;
Therapy
;
Hepatocellular Carinoma
Recommended Citations
Refworks
EndNote
RIS
Mendeley
Citations
Reyes, R. (2016).
Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy
[Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086
APA Style (7th edition)
Reyes, Ryan.
Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy.
2016. Ohio State University, Master's thesis.
OhioLINK Electronic Theses and Dissertations Center
, http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086.
MLA Style (8th edition)
Reyes, Ryan. "Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy." Master's thesis, Ohio State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086
Chicago Manual of Style (17th edition)
Abstract Footer
Document number:
osu1461275086
Download Count:
352
Copyright Info
© 2016, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.